PROVIDER *Update*

CONTRACTUAL | JANUARY 9, 2025 | UPDATE 25-025m | 3 PAGES

Medication Trend Updates and Drug Benefit Changes – 1st Quarter 2025

Review drug list changes and medication safety issues

Stay up to date with information about:

- Voluntary withdrawal of Oxbryta® from the market due to safety concerns
- Changes to the Medi-Cal drug benefits for the first quarter of 2025.

Voluntary withdrawal of Oxbryta from the market due to safety concerns

On September 25, 2024, Pfizer Inc., the manufacturer of Oxbryta (voxelotor), approved for treating sickle cell disease, announced it is voluntarily withdrawing the medication from the market. The company is also discontinuing all active clinical trials and expanded access programs for Oxbryta because recent data indicate the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.

In post marketing clinical trials of Oxbryta, Pfizer reported more deaths and a higher rate of vaso-occlusive crisis (severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues) in patients with sickle cell disease receiving Oxbryta compared to placebo. In addition, in two real-world registry studies, Pfizer also observed a higher rate of vaso-occlusive crisis in patients with sickle cell disease receiving Oxbryta.

The Food and Drug Administration (FDA) alerted patients and health care professionals about the withdrawal and advised providers to stop prescribing Oxbryta. Patients should contact their health care professional about stopping Oxbryta and starting another treatment option. The FDA had been undergoing a safety review of the post-marketing data prior to Pfizer's withdrawal of the drug.

Changes to Medi-Cal drug benefits

The Pharmacy Advisory Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the Pharmacy Advisory Committee reviews Medi-Cal drug benefits to determine changes. A table listing some recent changes is available on page 2. The list contains brand-name

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups

PROVIDER SERVICES

CalViva Health Medi-Cal (including ECM and CS providers) – 888-893-1569

PROVIDER PORTAL

provider.healthnetcalifornia.com

prescription medications, status, other medication choices, and comments for the first quarter of 2025.

A complete list of formularies for all products, including the Medi-Cal Drug Lists, is available on the Pharmacy Information for Providers page on the provider website at https://bit.ly/PharmacyInformationforProviders.

For medical drug benefits, refer to *Outpatient Pharmaceuticals (Submitted Under Medi-Cal Benefit)* section of the Medi-Cal Fee-for Service CalViva Health Prior Authorization List at https://bit.ly/HealthNetPriorAuthorizations.

Pharmacy help lines

For more information regarding changes to the Medi-Cal medical benefit drugs, contact the proper pharmacy phone number listed.

Additional information

Providers are encouraged to access the provider portal online at provider.healthnetcalifornia.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

Changes to the CalViva Health Medi-Cal drug benefits

Medication	Status	Formulary alternative(s)	Comments
Oral preparation			
Lazcluze™ (lazertinib) tablet	Carved out to state		A kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Livdelzi® (seladelpar) capsule	Carved out to state		A peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Voranigo® (vorasidenib) tablet	Carved out to state		An isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.

Changes to the CalViva Health Medi-Cal drug benefits, *continued*

Medication	Status	Formulary alternative(s)	Comments
Injectable preparation			
Lymphir™ (denileukin diftitox-cxdl) single-dose vial	Medical benefit[1]		An IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy
Niktimvo™ (axatilimab-csfr) single-dose vial	Medical benefit[1]		A colony stimulating factor-1 receptor (CSF-1R)-blocking antibody indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Tecelra® (afamitresgene autoleucel) suspension	Medical benefit[1]		A melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
Yorvipath® (palopegteriparatide) single-patient-use prefilled pen	Medical benefit[1]		A parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults.

Note: The information above is subject to change. Please refer to the Prior Authorization List at https://bit.ly/HealthNetPriorAuthorizations for the most up-to-date information.

[1] Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.